Midostaurin (PKC412)

Base Information

• Chemical Name: Midostaurin (PKC412)
• CAS No.: 120685-11-2
• Molecular Formula: C35H30 N4 O4
• Molecular Weight: 570.648
• Hs Code.: 29329990
• DSSTox Substance ID: DTXSID40923522
• Mol file: 120685-11-2.mol

Synonyms:C35H30N4O4;Midostaurin (PKC412);SCHEMBL1287888;DTXSID40923522;HB0521;Midostaurin;4'-N-benzoylstaurosporine

Chemical Property of Midostaurin (PKC412)

Chemical Property:

• Melting Point: 235-260℃
• Boiling Point: °Cat760mmHg
• PKA: 14.19±0.70(Predicted)
• Flash Point: °C
• PSA: 77.73000
• Density: 1.46g/cm³
• LogP: 6.23560
• Storage Temp.: Store at 2-8
• Solubility.: Soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml),
• XLogP3: 4.7
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 3
• Exact Mass: 570.22670545
• Heavy Atom Count: 43
• Complexity: 1180

Purity/Quality:

99%min, ^*data from raw suppliers

Midostaurin ^*data from reagent suppliers

Safty Information:

• Hazard Codes: T
• Statements: 36/37/38

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1(C(C2N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N(C7=C53)C1(O2)C)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC
• Isomeric SMILES: C[C@]1([C@@H]([C@@H]2N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N(C7=C53)[C@]1(O2)C)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC
• Recent ClinicalTrials: Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML
• Description: PKC-412 (120685-11-2) is a broad spectrum kinase inhibitor. Inhibited kinases include, but are not limited to; PKA, PKC, S6 Kinase, KDR, PKC, Akt, EGFR, VEGFR, PDGFR, c-kit, and FLT-3. Acute myeloid leukemia related mutant forms of FLT-3 are also inhibited both in vitro and in vivo. PKC-412 has been demonstrated to induce apoptosis and shows broad antiproliferative activity in various tumor cell lines. Cell Permeable
• Uses: Midostaurin was shown to possess antiproliferative characteristics via inhibition of protein kinase C, kinase insert domain receptor, and c-kit. Midostaurin is used as a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms (α, β, γ), PDFRβ, VEGFR2, Syk, PKCη, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity. Due to this act which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors. Midostaurin was shown to possess antiproliferative characteristics via inhibition of protein kinase C, kinase insert domain receptor, and c-kit.